Gut- and Vaginal Microbiome Composition in Association With PCOS

NCT ID: NCT05706922

Last Updated: 2024-09-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-11-16

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects up to 10% of the reproductive-aged women worldwide. The etiology is still unknown and treatment therefore remains symptomatic. Studies indicate a possible role of the gut microbiome in the pathology of PCOS. PCOS women have a disturbed gut microbiome, with certain species associated with the PCOS characteristics:hyperandrogenism, ovarian dysfunction, obesity, glucose intolerance and insulin resistance. Although differences have been found in gut microbiome composition between PCOS and healthy women, the literature is inconclusive regarding the difference in gut microbiome biodiversity. Studies examining the vaginal microbiome in PCOS women show consistent results with specific species in the vaginal microbiome. However, there are only few studies on the vaginal microbiome in PCOS women and no studies have yet investigated the correlation between sex-specific hormones and PCOS characteristics. More research is needed to understand the function of the microbiome in the pathophysiology of PCOS, so that this can offer perspectives in future therapies.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Polycystic Ovary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Polycystic ovary syndrome (PCOS)

* Hormonal screening
* Vaginal swab
* Fecal sample
* Blood samples
* Food Frequency Questionnaire

Venous blood sample, vaginal swab

Intervention Type OTHER

Venous blood samples and vaginal swab will be obtained on the same day.

Control group

* Hormonal screening
* Vaginal swab
* Fecal sample
* Blood samples
* Food Frequency Questionnaire

Venous blood sample, vaginal swab

Intervention Type OTHER

Venous blood samples and vaginal swab will be obtained on the same day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Venous blood sample, vaginal swab

Venous blood samples and vaginal swab will be obtained on the same day.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Caucasian
* Willing to provide vaginal swab and stool sample
* Willing to provide informed consent
* Sufficient command of the Dutch language
* Diagnosed with PCOS at Erasmus MC using the Rotterdam criteria by the presence of at least two of the following criteria
* Clinical or biochemical hyperandrogenism (modified Ferriman-Gallway score \>5; testosterone level \>2nmol/L, Free Androgen Index \> 2.9)
* Oligomenorrorrhea or amenorrhea
* Polycystic ovaries.

Exclusion Criteria

* BMI \<18
* Smoking
* Diabetes Mellitus or use of insulin sensitizer
* Chronic and acute infection diseases
* Endometriosis (American Fertility Score (AFS) III/IV)
* Elevated prolactin levels, thyroid disease, Cushing disease or gastro-intestinal disease
* The use of hormonal contraceptives, and other steroid hormones in the last 3 months
* Use of antibiotics, probiotics or laxatives in the last 3 months
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Erasmus Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sam Schoenmakers

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sam Schoenmakers, Dr. drs.

Role: PRINCIPAL_INVESTIGATOR

Division of Obstetrics and Fetal Medicine, Department of Obstetrics and Gynecology

Joop S.E. Laven, Prof. dr.

Role: STUDY_DIRECTOR

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Erasmus University Medical Center

Rotterdam, South Holland, Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xu Shan Gao, drs.

Role: CONTACT

+31631016348

Sam Schoenmakers, Dr. drs.

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xu Shan Gao, Drs

Role: primary

+31631016348

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL80648.078.22

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Microbiome and Polycystic Ovaries
NCT04836910 NOT_YET_RECRUITING